RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis
Cell plasticity is a crucial hallmark leading to cancer metastasis. Upregulation of Rho/ROCK pathway drives actomyosin contractility, protrusive forces, and contributes to the occurrence of highly invasive amoeboid cells in tumors. Cancer stem cells are similarly associated with metastasis, but how...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
EMBO Press
2021
|
_version_ | 1826287662340767744 |
---|---|
author | Tognoli, ML Vlahov, N Steenbeek, S Grawenda, AM Eyres, M Cano-Rodriguez, D Scrace, S Kartsonaki, C von Kriegsheim, A Willms, E Wood, MJ O'Neill, E Rots, MG van Rheenen, J Pankova, D |
author_facet | Tognoli, ML Vlahov, N Steenbeek, S Grawenda, AM Eyres, M Cano-Rodriguez, D Scrace, S Kartsonaki, C von Kriegsheim, A Willms, E Wood, MJ O'Neill, E Rots, MG van Rheenen, J Pankova, D |
author_sort | Tognoli, ML |
collection | OXFORD |
description | Cell plasticity is a crucial hallmark leading to cancer metastasis. Upregulation of Rho/ROCK pathway drives actomyosin contractility, protrusive forces, and contributes to the occurrence of highly invasive amoeboid cells in tumors. Cancer stem cells are similarly associated with metastasis, but how these populations arise in tumors is not fully understood. Here, we show that the novel oncogene RASSF1C drives mesenchymal-to-amoeboid transition and stem cell attributes in breast cancer cells. Mechanistically, RASSF1C activates Rho/ROCK via SRC-mediated RhoGDI inhibition, resulting in generation of actomyosin contractility. Moreover, we demonstrate that RASSF1C-induced amoeboid cells display increased expression of cancer stem-like markers such as CD133, ALDH1, and Nanog, and are accompanied by higher invasive potential in vitro and in vivo. Further, RASSF1C-induced amoeboid cells employ extracellular vesicles to transfer the invasive phenotype to target cells and tissue. Importantly, the underlying RASSF1C-driven biological processes concur to explain clinical data: namely, methylation of the RASSF1C promoter correlates with better survival in early-stage breast cancer patients. Therefore, we propose the use of RASSF1 gene promoter methylation status as a biomarker for patient stratification.
|
first_indexed | 2024-03-07T02:02:01Z |
format | Journal article |
id | oxford-uuid:9db14dae-c88d-482c-b8c9-b28c3c793a7b |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T02:02:01Z |
publishDate | 2021 |
publisher | EMBO Press |
record_format | dspace |
spelling | oxford-uuid:9db14dae-c88d-482c-b8c9-b28c3c793a7b2022-03-27T00:45:06ZRASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9db14dae-c88d-482c-b8c9-b28c3c793a7bEnglishSymplectic Elements EMBO Press2021Tognoli, MLVlahov, NSteenbeek, SGrawenda, AMEyres, MCano-Rodriguez, DScrace, SKartsonaki, Cvon Kriegsheim, AWillms, EWood, MJO'Neill, ERots, MGvan Rheenen, JPankova, DCell plasticity is a crucial hallmark leading to cancer metastasis. Upregulation of Rho/ROCK pathway drives actomyosin contractility, protrusive forces, and contributes to the occurrence of highly invasive amoeboid cells in tumors. Cancer stem cells are similarly associated with metastasis, but how these populations arise in tumors is not fully understood. Here, we show that the novel oncogene RASSF1C drives mesenchymal-to-amoeboid transition and stem cell attributes in breast cancer cells. Mechanistically, RASSF1C activates Rho/ROCK via SRC-mediated RhoGDI inhibition, resulting in generation of actomyosin contractility. Moreover, we demonstrate that RASSF1C-induced amoeboid cells display increased expression of cancer stem-like markers such as CD133, ALDH1, and Nanog, and are accompanied by higher invasive potential in vitro and in vivo. Further, RASSF1C-induced amoeboid cells employ extracellular vesicles to transfer the invasive phenotype to target cells and tissue. Importantly, the underlying RASSF1C-driven biological processes concur to explain clinical data: namely, methylation of the RASSF1C promoter correlates with better survival in early-stage breast cancer patients. Therefore, we propose the use of RASSF1 gene promoter methylation status as a biomarker for patient stratification. |
spellingShingle | Tognoli, ML Vlahov, N Steenbeek, S Grawenda, AM Eyres, M Cano-Rodriguez, D Scrace, S Kartsonaki, C von Kriegsheim, A Willms, E Wood, MJ O'Neill, E Rots, MG van Rheenen, J Pankova, D RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis |
title | RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis |
title_full | RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis |
title_fullStr | RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis |
title_full_unstemmed | RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis |
title_short | RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis |
title_sort | rassf1c oncogene elicits amoeboid invasion cancer stemness and extracellular vesicle release via a src rho axis |
work_keys_str_mv | AT tognoliml rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT vlahovn rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT steenbeeks rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT grawendaam rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT eyresm rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT canorodriguezd rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT scraces rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT kartsonakic rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT vonkriegsheima rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT willmse rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT woodmj rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT oneille rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT rotsmg rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT vanrheenenj rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis AT pankovad rassf1concogeneelicitsamoeboidinvasioncancerstemnessandextracellularvesiclereleaseviaasrcrhoaxis |